OncoMatch/Clinical Trials/NCT03484299

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Is NCT03484299 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Gemcitabine and FOLFIRINOX for pancreas cancer.

Phase 1RecruitingUniversity of LouisvilleNCT03484299Data as of May 2026

Treatment: Gemcitabine · FOLFIRINOX — Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Disease stage

Required: Stage III

Lab requirements

Kidney function

gfr > ml/min/1.73m2

Liver function

ast/alt >3 times upper limit of normal

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of Louisville · Louisville, Kentucky

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify